Abstract:
PURPOSE: A benzoic acid amide compound is provided to have excellent a skin-whitening effect without side effects by suppressing melanin generation and decreasing tyrosinase activity. CONSTITUTION: A benzoic acid amide compound, an isomer thereof, pharmaceutically-acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof is represented by chemical formula 1. In the chemical formula 1: each of R1, R3, and R4 is independently selected from hydrogen, hydroxy, C1-C5 alkoxy, C3-C6 cycloalkoxy, aryloxy, and C1-C15 haloalkoxy; R2 is selected from hydrogen, C1-C5 alkyl, C3-C6 cycloalkyl, aryl, and C1-C5 haloalkyl; and n is an integer from 1-5.
Abstract:
PURPOSE: A slimming cosmetic composition containing 2-cyclopentene-1-one oxime derivative is provided to promote lipid lysis in adipocytes(3T3-L1) and to reduce body fat. CONSTITUTION: A slimming cosmetic composition contains 2-cyclopentene-1-one oxime derivatives compound of chemical formula 1 or pharmaceutically acceptable salt as an active ingredient. The cosmetic composition induces decrease of neutral fat by promoting lipid lysis. The cosmetic composition is used in the form of emulsion, lotion, cream, gel, oil, spray, ointment, powder, compact, pack cleanser, shampoo, rinse, patch, or pad.
Abstract:
화학식 1로 나타내어지는 2-사이클로펜텐-1-온 옥심유도체를 포함하는 비만, 이상지질혈증, 당뇨 등과 같은 지방대사질환 예방 및 치료용 약학조성물이 개시된다. 구체적으로 상기 화합물은 분화된 지방세포 (3T3-L1)에서의 지방분해를 촉진시켜 결과적으로 체내 지방을 감소시킴으로써, 비만, 이상지질혈증, 당뇨 등과 같은 지방대사 질환의 예방 및 치료에 이용될 수 있다. 화학식 1에서 R 1 은 선형 또는 분지형 C 1 -C 6 알킬기, 또는 사이클로알킬기, 또는 치환기를 갖거나 갖지 않는 페닐기를 의미하고, R 2 는 치환기를 가지거나 가지지 않는 방향족기를 의미한다.
Abstract:
PURPOSE: A pharmaceutical composition containing 2-cyclopentene-1-one oxime derivative is provided to promote adipose lysis in adipocytes(3T3-L1) and to prevent and treat lipid metabolic diseases including obesity and diabetes. CONSTITUTION: A pharmaceutical composition for preventing and treating lipid metabolic diseases contains 2-cyclopenten-1-one oxime derivative compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In chemical formula 1, R1 is linear or branched C1-C10 alkyl group or C3-C7 cycloalkyl group, or phenyl group with or without substituent. The phenyl group is denoted by chemical formula 2. The pharmaceutical composition is used for preventing and treating obesity, diabetes, or dyslipidemia.
Abstract:
Triazolopyridazine derivatives are provided to inhibit acetyl-CoA carboxylase 2(ACC2), so that the compounds are useful for prevention and treatment of obesity, diabetes, hyperlipidemia and metabolic syndrome-related disease. Triazolopyridazine derivatives represented by the formula(1) have inhibitory effects on acetyl-CoA carboxylase 2, wherein X is hydrogen, pyridyl, thiophenyl, furanyl or phenyl optionally substituted by C1-5 alkyl, C1-5 alkoxy, hydroxy or halogen; Y is pyridine, thiophene or NHR2; Z is O, S, NH, methylene, ethylene or -CH(CH3)-; R1 is methyl, hydroxy or hydroxy methyl; R2 is hydrogen, C1-7 alkyl, C3-8 cycloalkyl optionally substituted by hydroxy or C1-7 alkyl, or phenyl optionally substituted by C1-5 alkyl; R3 is hydrogen, hydroxy, C1-5 alkyl, C1-5 alkoxy or halogen; R4 is hydrogen, hydroxy, C1-5 alkyl, C1-5 alkoxy, trifluoromethyl, C1-5 alkoxycarbonyl or halogen; and W is bond, C1-2 alkylene, alkenylene or alkynylene.
Abstract:
본 발명은 후보 물질을 처리한 피부 각질 세포에서 연장 효소(elongase)의 발현 정도를 확인하는 단계를 포함하는 아토피 피부염 개선용 물질 스크리닝 방법을 개시한다. 또한 본 발명은 피부의 연장 효소 발현 정도 분석부를 포함하는 아토피 피부염 진단 키트를 개시한다.
Abstract:
본명세서는비대칭탄소원자에아민기가결합된화합물의입체이성질체혼합물을카이랄보조체및 염-형성보조화합물과혼합시키는단계를포함하는입체이성질체혼합물의카이랄분할방법에관한것이다. 이때, 카이랄보조체는-디아실타르타르산유도체산, 보다구체적으로 2,3-디벤조일-타르타르산또는-디--톨루오일타르타르산이고, 염-형성보조화합물은만델산또는캄포르술폰산이며, 이러한방법에의하면높은수준의광학순도를가지는광학이성질체를얻는것이가능하다. 따라서, 본발명의일 측면에따른방법은약학또는화장품분야에서높은광학순도를갖는광학이성질체를제조하고자하는경우에유용하게사용될수 있다.